What is the mechanism of action of Romiplostim?

Romiplostim (Romiplostim) is a TPO-RA that has been used in adults with chronic immune thrombocytopenia (ITP) for more than 11 years. The use of romiplostim was recently approved in the United States and the European Union, and its use in adult patients has been expanded to include patients with newly diagnosed ITP. Romigrastim is currently being studied for its efficacy in severe aplastic anemia, chemotherapy-induced thrombocytopenia, and several other thrombocytopenias.

Romigrastim is a peptibody containing four TPO-R binding domains, has high affinity for TPO-R (MPL) and a carrier Fc domain, and has no sequence homology with endogenous TPO. Romiplostimbinds to and activates TPO-R on megakaryocyte precursors in the bone marrow, where it binds in the same manner as endogenous TPO and can displace TPO from its receptor. Romiplostimactivates many of the same pathways as TPO, resulting in sustained improvements in platelet counts in patients with ITP after continued treatment. Preclinical and clinical data suggest that romiplostim also has immunomodulatory effects.

RomiplostimThe original drug has been approved by the State Food and Drug Administration for marketing. Due to its short time on the market, it is not included in the scope of medical insurance. It may be difficult to purchase it domestically. The price of the original version in Hong Kong may be RMB 10,000 per pill (the price may fluctuate due to exchange rates). The price of the European version of romiplostim the original drug may be 11,000 RMB per pill, the German version may be 9,850 RMB per pill, and the Hong Kong version may be 8,900 RMB per pill (the price may fluctuate due to the exchange rate). The ingredients of the drugs are basically the same. For specific prices and drug details, please consult Yaode’s medical consultant.